Supplemental material
Human Vaccines & Immunotherapeutics
Volume 13, 2017 - Issue 10
Product Review - Solicited
Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine
, , 
&
Ningshao XiaState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, PR China;School of Life Science, Xiamen University, Xiamen, Fujian, PR Chinahttps://orcid.org/0000-0003-0179-5266
https://orcid.org/0000-0003-0179-5266 & Reprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related Research Data
Globocan 2012
Source:
Wiley
HPV Types for Vaccines and Screening Tests
Source:
Wiley
Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease
Source:
BioMed Central
Human papilloma virus vaccination: impact and recommendations across the world.
Source:
SAGE Publications
HPV Vaccination Guideline Update
Source:
Wiley
HPV in Anal Cancers
Source:
Wiley
Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: a literature review.
Source:
Elsevier BV
Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11.
Source:
Informa UK Limited
Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies
Source:
Elsevier BV
Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years.
Source:
Informa UK Limited
Functional epitopes on human papillomavirus capsid
Source:
Wiley
From the monovalent to the nine-valent HPV vaccine
Source:
Elsevier BV
Human papillomavirus: the burden of infection.
Source:
Ovid Technologies (Wolters Kluwer Health)
What we talk about when we talk about HPV coverage
Source:
Massachusetts Medical Society
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil ® ): A Review of Its Use in the Prevention of Premalignant Anogenital Lesions, Cervical and Anal Cancers, and Genital Warts
Source:
Springer Science and Business Media LLC
Human papillomavirus: a review
Source:
Elsevier BV
Immunogenicity and safety of the 9-valent HPV vaccine in men.
Source:
Elsevier BV
An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany
Source:
Informa UK Limited
Vaccine Analysis: Strategies, Principles, and Control
Source:
Springer Berlin Heidelberg
HPV Vaccine and Boys
Source:
Wiley
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.
Source:
Elsevier BV
Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials
Source:
Elsevier
Public health value of universal HPV vaccination.
Source:
Elsevier BV
Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis
Source:
Elsevier BV
The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon
Source:
Informa UK Limited
Currently approved prophylactic HPV vaccines.
Source:
Informa UK Limited
Economic evaluations of massive HPV vaccination: within-study and between study variations in incremental cost per QALY gained.
Source:
Elsevier BV
Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine.
Source:
Elsevier BV
Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease
Source:
American Association for Cancer Research Inc.
Exploring lay public and dental professional knowledge around HPV transmission via oral sex and oral cancer development.
Source:
BioMed Central
A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women
Source:
Massachusetts Medical Society
Correlation between mouse potency and in vitro relative potency for human papillomavirus Type 16 virus-like particles and Gardasil vaccine samples.
Source:
Informa UK Limited
Safety, tolerability, and immunogenicity of gardasil given concomitantly with Menactra and Adacel.
Source:
American Academy of Pediatrics (AAP)
Results From a Randomized Open Trial
Source:
Ovid Technologies (Wolters Kluwer Health)
Systematic review of human papillomavirus vaccine coadministration.
Source:
Elsevier BV
Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women.
Source:
American Medical Association (AMA)
New Policy for the Second Decade of the Vaccination Program
Source:
American Medical Association (AMA)
Estimating The Cost-Effectiveness Profile of A Universal Vaccination Programme With A Nine-Valent Hpv Vaccine In Austria
Source:
Elsevier BV
9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV.
Source:
Informa UK Limited
Effectiveness of the human papillomavirus (types 6, 11, 16, and 18) vaccine in the treatment of children with recurrent respiratory papillomatosis
Source:
Elsevier BV
Oncogenic Herpes viruses.
Source:
Elsevier BV
The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model.
Source:
Informa UK Limited
Ten years of HPV vaccines: State of art and controversies
Source:
Elsevier BV
Cost-effectiveness of the nonavalent HPV vaccine
Source:
Wiley
Gardasil 9 joins the fight against cervix cancer
Source:
Informa UK Limited
Chimeric L1-L2 Virus-Like Particles as Potential Broad-Spectrum Human Papillomavirus Vaccines
Source:
American Society for Microbiology
Human papilloma viruses and cancer.
Source:
S. Karger AG
Monoclonal Antibodies to HPV-6 L1 Virus-like Particles Identify Conformational and Linear Neutralizing Epitopes on HPV-11 in Addition to Type-Specific Epitopes on HPV-6
Source:
Elsevier BV
Linking provided by
